TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06358339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEEM
Description: The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
Study: NCT04956302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Lactate
Description: Given PO
Study: NCT05230173

Intervention type: OTHER
Group type: OTHER
Intervention: Pragmatic
Description: Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team.

Intervention type: OTHER
Group type: OTHER
Intervention: Pragmatic
Description: Patients randomized to a strategy of switching TIM will be switched to one of the preferred agents recommended by clinical guidelines and covered by the patients' insurance formulary as part of routine care, and at the discretion of the site investigator and treating provider. No study-related medications will be provided.~Patients (and their providers) in either treatment arm will be allowed to stop or start new TIMs and other IBD-directed therapies in case of symptomatic relapse or intolerance to therapies, at the discretion of the treating provider-patient team.
Study: NCT05420103

Intervention type: OTHER
Intervention: Accelerated Stroke Ambulation Program
Description: Stroke Rehabilitation Program
Study: NCT06268431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxytocin rest
Description: 60-minute oxytocin rest
Study: NCT05595369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Paxlovid 25 day dosing
Description: Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Paxlovid 15 day dosing
Description: Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
Study: NCT06453174

Intervention type: OTHER
Intervention: Adherence to the first prescribed antipsychotic medication
Description: We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.

Intervention type: OTHER
Intervention: Adherence to the first prescribed antipsychotic medication
Description: We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
Study: NCT05602636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, midazolam
Description: Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
Study: NCT04565392

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine 20 milligram tablet
Description: 1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
Study: NCT05602636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, midazolam
Description: Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, midazolam
Description: Patients will be provided with midazolam (up to 2 mg) if requested. No opioids will be administered before the incision. At the first patient complaint of pain, the intraoperative anesthesia team will document the quality and location of pain, and 50 microgram of fentanyl will be administered if the patient requested it or pain score more than 3
Study: NCT05185531

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PD-1 plus stereotactic body radiotherapy
Description: neoadjuvant PD-1(Tislelizumab) plus stereotactic body radiotherapy (8 Gy × 3 fractions) in resectable HCC
Study: NCT04952506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does
Study: NCT04565392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 20 milligram tablet
Description: 1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
Study: NCT04952506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F1 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-349 F2 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D113 Tab.
Description: 1T Single does
Study: NCT05433870

Intervention type: OTHER
Intervention: Whether the PE or E patient combined with PRES
Description: According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
Study: NCT05480917

Intervention type: OTHER
Group type: OTHER
Intervention: Patients receiving PsoPlus care
Description: As stated before, both outcomes (via VOS) and costs will be collected. Data on clinical outcomes, such as skin clearance, in the VOS will be collected during follow-up visits at our clinic. Outcomes which are assessed via a questionnaire will be collected using a specialized patient platform (PsoQuest). In addition, for this study the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire will need to be filled in. When consultations do not coincide with the time points, data will be collected by a study nurse on a study visit (at our department or the patient's home) and via PsoQuest. A 1 month period will be in place around the time point, meaning that the data can be collected 2 weeks beforehand or afterwards. Cost data will be collected using the TD-ABC approach over the full cycle of care.
Study: NCT06172972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atraumatic nursing care
Description: Children in the intervention group were allowed to choose a distracting method (foam balloons, stress balls, musical books) to be occupied with during the procedure
Study: NCT04846452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
Description: Patients with non-squamous NSCLC will receive sintilimab, anlotinib hydrochloride, pemetrexed, and cisplatin or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
Description: Patients with squamous NSCLC will receive sintilimab, anlotinib hydrochloride, albumin paclitaxel, and carboplatin.
Study: NCT06343610

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active product
Description: Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredients.
Study: NCT06184672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: the area is disinfected by the use of 0.5% chlorhexidine digluconate alcohol solution. The physiotherapist in charge of the intervention uses sterile nitrile gloves, using dry needling needles with dimensions of 0.30 x 50 mm is used. This technique, designed by Hong, applies speed both at the entrance, in order to provoke the local spasm response and at the exit. The inputs and outputs are performed until the REL disappears or until the tolerance threshold of the patient is reached.~Immediately after performing the puncture, ischemic compression is performed on the treated muscle, in order to decrease the duration and intensity of post-puncture pain. For this, a digital pressure is made to the point where the patient's sensation ceases to be pressure and becomes pain. Once the patient is noted that pain is repeated again the art up to a total of 2 minutes
Study: NCT05387941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic
Description: one drop daily in each eye with retinopathy of prematurity of a predefined stage.
Study: NCT05539092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changing angle of bed
Description: Before the cardiac catheterization procedure: patients' demographic characteristics and health relevant data will be collected on the first day of admission. the researcher will change angle of bed from 15° to 45°.
Study: NCT05815043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-sodium intake
Description: Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-sodium intake
Description: Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
Study: NCT05854056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated rehabilitation protocol
Description: See Arms section
Study: NCT06440915

Intervention type: OTHER
Group type: OTHER
Intervention: Theraputic drug monitoring
Description: High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
Study: NCT03991299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 200 UNT Injection
Description: Botox will be injected into duodenums of subjects by endoscopy.
Study: NCT06440915

Intervention type: DRUG
Group type: OTHER
Intervention: Isavuconazole
Description: Isavuconazole
Study: NCT05714514

Intervention type: DRUG
Intervention: Imlifidase administered in the ConfIdeS study
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.

Intervention type: OTHER
Intervention: Best available treatment administered in the ConfIdeS study
Description: Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
Study: NCT06178991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza and COVID-19 Combination A
Description: Combined influenza and Pfizer-BioNTech COVID-19 Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: Licensed influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: Licensed influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed influenza vaccine
Description: Licensed influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine
Description: Pfizer-BioNTech COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine
Description: Pfizer-BioNTech COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine
Description: Pfizer-BioNTech COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza and COVID-19 Combination B
Description: Combined influenza and Pfizer-BioNTech COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza and COVID-19 Combination B
Description: Combined influenza and Pfizer-BioNTech COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline Solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline Solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational influenza vaccine
Description: Investigational influenza vaccine
Study: NCT06665386

Intervention type: PROCEDURE
Intervention: hypothermia
Description: Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL
Study: NCT04823884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal chevron osteotomy
Description: Through a 4-cm-long dorsomedial skin incision the V-shaped osteotomy with the apex 1-2 mm superior to the center of the metatarsal head is performed. The angle of the chevron is 60° to 90°. The direction of the osteotomy is angled toward the center of the third metatarsal head. After shifting the metatarsal head laterally, fixation is achieved by usage of one cannulated screw (3.0 mm or 2.5mm). Prominent bone ridges are resected with a saw. A distal soft tissue procedure is performed in every case through the same skin incision. The adductor hallucis tendon is detached from its insertion at the phalangeal bone and from the lateral border of the fibular sesamoid. The transverse intermetatarsal ligament is released and a T-shaped capsulotomy is performed to allow reposition of the sesamoids. Sesamoid position is controlled by sight. After closing of the medial capsula skin is closed with nylon sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive distal chevron osteotomy
Description: The osteotomy is performed percutaneously through a dorsomedial incision of 3-5 mm. An electric motor-driven machine used for the osteotomy. To prevent overheating the reamer is frequently rinsed with sterile saline. The medial eminence is excised and the V-shaped osteotomy is performed. The apex of the osteotomy is identified by fluoroscopy and centered 1-2 mm superior to the center of the metatarsal head. The angle of the osteotomy amounts to 60-90 degrees as well. Bone debris is washed out with sterile saline. A lateral soft-tissue release is undertaken through a separate lateral incision of 3-5 mm. The distal fragment is shifted laterally and fixed with a canulated screw of 3.5mm. Residual bone ridges are reamed. Position of the metatarsal head and the K-wire is controlled by fluoroscopy. The skin is closed with a nylon sutures.
Study: NCT04766944

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04105231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone, encapsulated tablet.
Study: NCT05596448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coccygeal nerve radiofrequency ablation
Description: During the procedure, after imaging the sacral and coccygeal corns with ultrasonography, a radiofrequency ablation needle is inserted at the level of the coccygeal horn and radiofrequency ablation is applied at 90 degrees for 60 seconds.
Study: NCT04754607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Eight target points (superior, mediolateral, inferior border of the right and left thyroid lobes, right and left sides of the isthmus) will be marked with a surgical pen by determining the thyroid borders on the skin by thyroid ultrasonography by the specialist physician. Low-level laser (28.57 J / cm2) fixed applications will be made on the thyroid gland, approximately 1 cm from each other. In practice, the patient's neck will be maintained in the extension position. Each application will last 20 seconds and the radiant energy will be 2 J, the tip of the laser will be kept in contact with the skin and upright. Duration of treatment is 6 sessions 2 days a week. The cumulative dose will be 96 J.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Probes were placed in the sham laser group in a similar way as in the treatment group. The screen of the laser device was active; however, the energy was set as 0 J and the power as 0 mW , respectively,and the same operations were also performed.
Study: NCT05460325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab subcutaneous injection
Study: NCT05261178

Intervention type: OTHER
Intervention: Evaluation of satisfaction and the level of daily living activities using the prosthesis
Description: Evaluation of satisfaction with using the prosthesis with TAPES (Trinity Amputation and Prosthesis Experience Scale) and the level of daily living activities using the prosthesis with SF-36 (Short Form-36)
Study: NCT06670872

Intervention type: DRUG
Intervention: Eravacycline combination therapy group
Description: Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines.
Study: NCT06203106

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study: NCT06616831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training
Description: Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
Study: NCT06621238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Listen to Music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Listen to Music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Listen to Music